Cytiva

About Cytiva

At Cytiva, our mission is to advance and accelerate the development of therapeutics. With 15 000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers.  Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma, and contract manufacturers. 

  • IT
  • 2024
    On CPHI since
  • 5000+
    Employees
Company types
Biopharmaceutical company
Contact info

Products from Cytiva (1)

  • Supor™ Prime sterilizing grade filters

    Product Supor™ Prime sterilizing grade filters

    Supor™ Prime filters deliver high throughput for high concentration and high viscosity mAbs, proteins, and other challenging feeds. - Increased product recovery due to high throughput - Proven for feeds up to 220 g/L and 30 cP - Low adsorption of active ingredients and excipients - Scalable formats to gro...

Cytiva Resources (2)

  • Video Trends and Challenges in Sterile Filtration of High Concentration Drugs

    Drug formulations are changing, and the share of subcutaneous administration over intravenous infusion is increasing. Subcutaneous administration is seen to be the preferred approach both by patient and healthcare providers. Careful consideration is required when selecting a sterilizing grade filter for drug product filtration. With the development and manufacture of subcutaneous biologics come challenges in the sterilizing or bioburden reduction filtration of drug substance that is both highly concentrated (>100 g/L) and viscous (10-30 cP). Two significant problems are: The use of larger filters because of the high fouling properties of the feeds. This results in the loss of high value drug substance in hold-up volumes in both the filtration assembly and system. The relative scarcity of product during process development. This results in limited opportunities for meaningful filter benchmarking studies and can lead to sub-optimal filter selection. The relative value and availability of high concentration drug formulations limits the practicality of performing extensive evaluations of a range of sterile filters to identify the optimal selection. In this presentation we will share the approach we took, allowing us to undertake extensive filterability trials without the need to generate a high quantity of expensive product.
  • Video Novel Chromatography for Antibody Variants and Recombinant Proteins

    Developing purification protocols can be challenging for molecules beyond traditional mAbs such as bispecific antibodies, antibody fragments, and other recombinant proteins. Here we cover strategies to help simplify purification of some of these trickier molecules. This presentation covers: Aspects of designing a purification process for bispecific antibodies (using MabSelect™ VH3 resin) A novel affinity chromatography technology (Cytiva™ Protein Select™ resin) for purification of any recombinant protein